MedTrace Logo

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers

NCT06025318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-11-21

No results posted yet for this study

Summary

This is an open-label, balanced, randomized, two-period, crossover, single dose study to compare the relative bioavailability in normal healthy, adult, human subjects under Fed and Fasting conditions. Subjects will receive a single oral dose of probenecid oral suspension (100 mg/mL) under fed and fasted conditions.

Conditions

  • Relative Bioavailability

Interventions

DRUG

PanCytoVir™

PanCytoVir™ 100 mg/mL oral suspension

Sponsors & Collaborators

  • TrippBio, Inc.

    lead INDUSTRY

Principal Investigators

  • David E Martin, PharmD · TrippBio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2024-09-30
Completion
2024-10-15
FDA Drug
Yes

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06025318 on ClinicalTrials.gov